Status:
RECRUITING
Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia
Lead Sponsor:
FANG HE
Conditions:
Preeclampsia
Perinatal Haemorrhage
Eligibility:
FEMALE
18-45 years
Phase:
PHASE3
Brief Summary
Low-dose aspirin (LDA) is considered to be the most effective agent to prevent preeclampsia (PE). At present, there is little exploration about the timing of aspirin discontinuation. Most internationa...
Detailed Description
This study aimed to optimize the strategy of aspirin to prevent preeclampsia, by exploring whether aspirin discontinuation at 28 weeks of gestation to prevent preterm PE is not inferior to 36 weeks of...
Eligibility Criteria
Inclusion
- At \<16 weeks of gestation, normal NT scan
- At least 1 high risk factor or at least 2 moderate risk factors
- Intend to receive prenatal examination and deliver in this institution
- Signed a written informed consent for participation in the study
Exclusion
- Aspirin initiated after 16 week
- Intolerant or allergic to aspirin
- Aspirin adherence was \<80%
- Miscarriage or termination of pregnancy before randomization
- drop out (do not return to the hospital for delivery).
- Lost to follow-up
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT06111079
Start Date
November 1 2023
End Date
December 31 2024
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
FANG HE
Guangzhou, Guangdong, China, 510150